| |
The BD FACSymphony A5 SE Cell Analyzer adds high-sensitivity detectors to detect the full spectrum of emitted light. Unmix spectral data live, all while retaining the flexibility of familiar compensation-based workflows. Learn more.
|
|
Today's Big NewsNov 10, 2022 |
| By Nick Paul Taylor AstraZeneca has tossed out two early-phase drug development programs in its quarterly review, adding a Moderna-partnered solid tumor candidate and in-house chronic kidney disease treatment to its discard pile. |
|
|
|
By Annalee Armstrong The FDA was pretty clear a year and a half ago that BrainStorm Cell Therapeutics’ amyotrophic lateral sclerosis therapy was not ready for prime time—but perhaps this latest rejection will really send the message home. |
By Nick Paul Taylor Veru has lost a split decision at its FDA advisory committee, with the experts voting eight to five against the known and potential benefit-risk profile of VERU-111 in hospitalized moderate to severe COVID-19 patients who are at high risk for acute respiratory distress syndrome. |
By Annalee Armstrong In order for Curis’ leukemia drug to survive, resources must be shifted, and, in today’s biotech landscape, that means layoffs and a slimming of other programs. |
By James Waldron Cyclacel once had high hopes for sapacitabine. But, despite making it as far as a phase 3 trial for acute myeloid leukemia as well as midstage studies for other cancers, the biotech has decided to give up and hand the rights back to Daiichi Sankyo. |
By Max Bayer Nordic Nanovector appeared to be on its deathbed after axing its lead asset in July. But the company will live to fight another day after acquiring fellow Norwegian biotech APIM Therapeutics. |
By Fraiser Kansteiner Biogen’s board has tapped former Sanofi chief Christopher Viehbacher to assume the CEO throne on November 14. Viehbacher will also take over the role of director from Vounatsos, who plans to stick around at the struggling biotech for a “limited period of time” to smooth the CEO switch, Biogen said in a securities filing. |
By Kevin Dunleavy Seven months after Seagen was rocked by the domestic abuse arrest of founder, chairman and CEO Clay Siegall and his subsequent resignation, the powerhouse Seattle biotech has found its new leader, appointing oncology veteran David Epstein as its CEO. Epstein, 59, spent more than 25 years at Novartis, building its oncology business from “initiation to the second largest in the world,” Seagen said in a release. |
By Joseph Keenan Excelya has brought on Veeva Systems’ suite of clinical trial management tools for data cleaning and reporting in clinical trials. |
By Joseph Keenan Alimentiv and Summit Clinical Research are joining forces to improve clinical trials for treatments being developed to address a chronic liver disease. |
Fierce podcastsDon't miss an episode |
| | This week on “The Top Line,” we dig into Philips’ revelation that it is laying off 4,000 workers and planning for even more restructuring. |
|
|---|
|
|
|
Tuesday, November 15, 2022 | 1pm ET / 10am PT In this webinar, learn how Medable is focused on improving access to clinical trials for patients, supporting the innovation of clinical trial delivery and offering greater choices for participation and engagement to patients. Register now.
|
|
| Webinar Twist Bioscience CSO Dr. Aaron Sato shares how Twist's tools for antibody discovery have been applied to identify antibodies against diverse and challenging targets. See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Presented by: Twist Bioscience |
| ResearchLearn more about adaptive ascending dose escalation designs and considerations for determining the optimal approach to meet your drug development objectives Sponsored by: Allucent |
| WhitepaperRead through this library of resources to find out how you can strengthen innovation and efficiency, improve safety and quality, and prioritize resources to support your long-term goals. Sponsored by: JLL |
| ResearchLearn more about adaptive ascending dose escalation designs and considerations for determining the optimal approach to meet your drug development objectives Sponsored by: Allucent |
| WhitepaperThis paper outlines how gene therapy supply chains are different from traditional biopharma products, as well as the factors that are essential to success. Sponsored by: Blue Matter |
| VideoRevolutionize your monoclonal antibody (mAb) manufacturing process with the Gibco™️ Efficient-Pro™️ Medium and Feed System. Watch our how-to video. Sponsored by: Thermo Fisher Scientific |
| WhitepaperWhat is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent |
| ResearchLearn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent |
| WhitepaperHow can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
| WhitepaperLearn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
| WebinarYpsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics |
| WhitepaperClarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent |
| WhitepaperLearn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent |
| eBookOrally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored By: Catalent |
| WhitepaperDid you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored By: Catalent |
| WhitepaperWhat are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
| |
|
